PMID- 28465354
OWN - NLM
STAT- MEDLINE
DCOM- 20180227
LR  - 20181202
IS  - 1573-4935 (Electronic)
IS  - 0144-8463 (Print)
IS  - 0144-8463 (Linking)
VI  - 37
IP  - 3
DP  - 2017 Jun 30
TI  - EGFR inhibition by (-)-epigallocatechin-3-gallate and IIF treatments reduces 
      breast cancer cell invasion.
LID - BSR20170168 [pii]
LID - 10.1042/BSR20170168 [doi]
AB  - Epidermal growth factor receptor (EGFR) expression is an important marker in 
      breast carcinoma pathology and is considered a pivotal molecule for cancer cell 
      proliferation, invasion and metastasis. We investigated the effects of 
      epigallocatechin-3-gallate (EGCG), the most active green tea catechin, in 
      combination with 6-OH-11-O-hydroxyphenanthrene (IIF), a synthetic retinoid X 
      receptor-gamma (RXRgamma) agonist, on three breast carcinoma cell lines: MCF-7, MCF-7TAM 
      and MDA-MB-231. EGFR and AKT activation and molecular markers of cell motility 
      and migration (CD44, extracellular matrix metalloproteinase (MMP) inducer 
      (EMMPRIN), MMP-2, MMP-9 and tissue inhibitor of metalloproteinases (TIMPs)) were 
      studied after EGCG and IIF treatments. The EGCG + IIF treatment was the most 
      active in down-regulating EGFR phosphorylation at Tyr(1068) in all the 
      investigated cell lines; p473AKT was also down-regulated in MCF-TAM cells. EGCG + 
      IIF was also the most active treatment in reducing the expression of markers of 
      invasion and migration in all the three cell lines: CD44, EMMPRIN, MMP-2 and -9 
      expression decreased, whereas TIMPs were up-regulated. Zymography and scratch 
      assay also confirmed the reduced invasion tendency. We considered that EGCG and 
      IIF treatments could alter the molecular network based on EGFR, CD44 and EMMPRIN 
      expression interdependence and reduced the migration tendency in MCF-7, MCF-7TAM 
      and MDA-MB-231 cells. These events only occurred in association with AKT 
      inactivation in MCF-7TAM cells. In conclusion, the combination of EGCG and IIF 
      significantly attenuated the invasive behaviour of breast carcinoma cells.
CI  - (c) 2017 The Author(s).
FAU - Farabegoli, Fulvia
AU  - Farabegoli F
AD  - Department of Pharmacology and Biotechnology (FaBiT), University of Bologna, 
      Bologna, Italy fulvia.farabegoli@unibo.it.
FAU - Govoni, Marzia
AU  - Govoni M
AD  - Department of Specialistic, Diagnostic and Experimental Medicine (DIMES), 
      University of Bologna, Bologna, Italy.
FAU - Spisni, Enzo
AU  - Spisni E
AD  - Department of Biological, Geological, and Environmental Sciences, (BiGea), 
      University of Bologna, Bologna, Italy.
FAU - Papi, Alessio
AU  - Papi A
AD  - Department of Biological, Geological, and Environmental Sciences, (BiGea), 
      University of Bologna, Bologna, Italy.
LA  - eng
PT  - Journal Article
DEP - 20170517
PL  - England
TA  - Biosci Rep
JT  - Bioscience reports
JID - 8102797
RN  - 0 (6-OH-11-O-hydroxyphenanthrene)
RN  - 0 (Phenanthrenes)
RN  - 0 (Protein Kinase Inhibitors)
RN  - 0 (Tissue Inhibitor of Metalloproteinase-1)
RN  - 136894-56-9 (Basigin)
RN  - 8R1V1STN48 (Catechin)
RN  - BQM438CTEL (epigallocatechin gallate)
RN  - EC 2.7.10.1 (EGFR protein, human)
RN  - EC 2.7.10.1 (ErbB Receptors)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 3.4.24.24 (Matrix Metalloproteinase 2)
RN  - EC 3.4.24.35 (Matrix Metalloproteinase 9)
SB  - IM
MH  - Basigin/metabolism
MH  - Breast Neoplasms/*drug therapy/metabolism/pathology
MH  - Catechin/*analogs & derivatives/pharmacology
MH  - Cell Line, Tumor
MH  - Cell Movement/*drug effects
MH  - Down-Regulation/drug effects
MH  - ErbB Receptors/*antagonists & inhibitors
MH  - Female
MH  - Humans
MH  - MCF-7 Cells
MH  - Matrix Metalloproteinase 2/metabolism
MH  - Matrix Metalloproteinase 9/metabolism
MH  - Neoplasm Invasiveness/*pathology
MH  - Phenanthrenes/*pharmacology
MH  - Phosphorylation/drug effects
MH  - Protein Kinase Inhibitors/pharmacology
MH  - Proto-Oncogene Proteins c-akt/metabolism
MH  - Signal Transduction/drug effects
MH  - Tissue Inhibitor of Metalloproteinase-1/metabolism
PMC - PMC5434892
OTO - NOTNLM
OT  - (-)-epigallocatechin-3-gallate (EGCG)
OT  - 6-OH-11-O-hydroxyphenantrene (IIF)
OT  - CD44
OT  - breast carcinoma
OT  - epidermal growth factor receptor
OT  - extracellular matrix metalloproteinase inducer
COIS- The authors declare that there are no competing interests associated with the 
      manuscript.
EDAT- 2017/05/04 06:00
MHDA- 2018/02/28 06:00
PMCR- 2017/05/17
CRDT- 2017/05/04 06:00
PHST- 2017/02/27 00:00 [received]
PHST- 2017/04/27 00:00 [revised]
PHST- 2017/05/02 00:00 [accepted]
PHST- 2017/05/04 06:00 [pubmed]
PHST- 2018/02/28 06:00 [medline]
PHST- 2017/05/04 06:00 [entrez]
PHST- 2017/05/17 00:00 [pmc-release]
AID - BSR20170168 [pii]
AID - 10.1042/BSR20170168 [doi]
PST - epublish
SO  - Biosci Rep. 2017 May 17;37(3):BSR20170168. doi: 10.1042/BSR20170168. Print 2017 
      Jun 30.